ERYTech: Dense newsflow to come in H2
CORPORATE, Fair Value EUR16.5 (+70%)
Erytech released unsurprising financials results for H1 with a solid cash position of EUR18.5m. The company is also giving updates on key clinical developments for Graspa: 1/ enrolment of the pivotal phase III in Acute Lymphoblastic Leukaemia is near completion and results are confirmed to be available in Q3 2014; and 2/ more than 20% of patients have been recruited in Acute Myeloid Leukaemia (AML) at a faster pace than expected. With the completion of the enrolment in the ALL Phase III, we expect the first patient treated in the US Phase I as well as the start of a clinical trial in solid tumours. Therefore, we expect several important announcements in H2.
Full report available to subscribers
Please contact firstname.lastname@example.org